Clearbridge Investments LLC Acquires 39,369 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Clearbridge Investments LLC raised its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 7.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 560,609 shares of the medical equipment provider's stock after purchasing an additional 39,369 shares during the quarter. Clearbridge Investments LLC owned 0.81% of Lantheus worth $45,011,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Daiwa Securities Group Inc. bought a new stake in shares of Lantheus during the first quarter worth $1,269,000. Nordea Investment Management AB grew its position in Lantheus by 42.6% during the 1st quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider's stock worth $2,932,000 after acquiring an additional 14,147 shares during the last quarter. Hancock Whitney Corp increased its holdings in Lantheus by 265.6% in the 1st quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider's stock worth $1,254,000 after purchasing an additional 14,639 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in Lantheus in the second quarter valued at about $290,000. Finally, Pitcairn Co. boosted its stake in shares of Lantheus by 117.0% during the first quarter. Pitcairn Co. now owns 8,364 shares of the medical equipment provider's stock valued at $521,000 after purchasing an additional 4,509 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Lantheus Trading Up 1.1 %

Shares of NASDAQ:LNTH traded up $1.22 during mid-day trading on Friday, hitting $107.79. The company had a trading volume of 296,412 shares, compared to its average volume of 997,925. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89. The firm has a fifty day moving average price of $103.86 and a 200 day moving average price of $87.00. The company has a market capitalization of $7.47 billion, a PE ratio of 16.46 and a beta of 0.50.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). The company had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. Lantheus's revenue for the quarter was up 22.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.40 EPS. As a group, research analysts forecast that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Redburn Atlantic initiated coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price objective for the company. Leerink Partners raised their price target on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research note on Thursday, July 11th. B. Riley increased their price objective on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, July 25th. Truist Financial decreased their price target on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research note on Thursday, August 1st. Finally, JMP Securities reduced their target price on Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $126.00.

Insider Transactions at Lantheus

In other Lantheus news, Director Gary J. Pruden sold 12,530 shares of the firm's stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total value of $1,190,851.20. Following the transaction, the director now directly owns 11,978 shares of the company's stock, valued at approximately $1,138,389.12. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Gary J. Pruden sold 12,530 shares of the stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total value of $1,190,851.20. Following the completion of the sale, the director now directly owns 11,978 shares of the company's stock, valued at approximately $1,138,389.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 40,852 shares of company stock valued at $3,922,001 over the last ninety days. 1.50% of the stock is owned by company insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.